JP2025516558A5 - - Google Patents

Info

Publication number
JP2025516558A5
JP2025516558A5 JP2024566255A JP2024566255A JP2025516558A5 JP 2025516558 A5 JP2025516558 A5 JP 2025516558A5 JP 2024566255 A JP2024566255 A JP 2024566255A JP 2024566255 A JP2024566255 A JP 2024566255A JP 2025516558 A5 JP2025516558 A5 JP 2025516558A5
Authority
JP
Japan
Prior art keywords
approximately
compound
administered
time
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516558A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/021604 external-priority patent/WO2023220098A1/en
Publication of JP2025516558A publication Critical patent/JP2025516558A/ja
Publication of JP2025516558A5 publication Critical patent/JP2025516558A5/ja
Pending legal-status Critical Current

Links

JP2024566255A 2022-05-09 2023-05-09 癌治療のためのメニン－ｍｌｌ阻害剤 Pending JP2025516558A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263339635P 2022-05-09 2022-05-09
US63/339,635 2022-05-09
PCT/US2023/021604 WO2023220098A1 (en) 2022-05-09 2023-05-09 Menin-mll inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025516558A JP2025516558A (ja) 2025-05-30
JP2025516558A5 true JP2025516558A5 (enExample) 2026-05-18

Family

ID=88730925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566255A Pending JP2025516558A (ja) 2022-05-09 2023-05-09 癌治療のためのメニン－ｍｌｌ阻害剤

Country Status (10)

Country Link
US (1) US20250295661A1 (enExample)
EP (1) EP4522174A4 (enExample)
JP (1) JP2025516558A (enExample)
KR (1) KR20250020447A (enExample)
CN (3) CN120514709A (enExample)
AU (1) AU2023269033A1 (enExample)
CA (1) CA3252288A1 (enExample)
IL (1) IL316829A (enExample)
MX (1) MX2024013787A (enExample)
WO (1) WO2023220098A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
AR125866A1 (es) * 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
KR20260099138A (ko) * 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
WO2025188611A1 (en) * 2024-03-04 2025-09-12 Dana-Farber Cancer Institute, Inc. Chemical matters for targeting leukemic complex proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
AU2019337547A1 (en) * 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
WO2020142557A1 (en) * 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
IL297039A (en) * 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
JP7891524B2 (ja) * 2021-08-11 2026-07-16 バイオメア フュージョン，インコーポレイテッド 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
ES2954361T3 (es) Métodos de uso de dipivefrina
JP2023522166A5 (enExample)
EP3429614B1 (en) Method of treating triple negative breast cancer
JP2011088921A (ja) 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
BR112018016517B1 (pt) Composições farmacêuticas incluindo uma droga antirretroviral e um intensificador farmacocinético, métodos operacionais das composições e kit com antirretroviral e intensificador
JP2015517523A5 (enExample)
JP2018516936A5 (enExample)
JP2023102787A (ja) 癌の治療におけるドセタキセルの長期使用
JP2019519573A (ja) がんを処置するための方法
JP2024517935A5 (enExample)
US11389424B2 (en) Methods and compositions for treating chemotherapy-induced diarrhea
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2023530001A (ja) ウイルス感染症の処置のための化合物
CN121218987A (zh) 雌激素受体降解剂和akt抑制剂的组合
JP2021020953A (ja) 血液癌治療のためのｈｄａｃ阻害剤およびプロテアソーム抑制剤または免疫調節性薬物を含む薬学的調合物
TW201628608A (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
JP6644479B2 (ja) がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
US20220339162A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors
US20230018980A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors
CN109789136B (zh) 用于预防或治疗结肠直肠癌的药物联合组合物
JP2023538186A (ja) 化学療法誘発性下痢を治療するための方法及び組成物
CN111494371B (zh) Pyr3的用途